Oncology drug pricing and price transparency
New cancer drugs commonly launch above $150,000-$250,000 per year in the US, with prices set without reference to benefit and hidden behind rebates; other countries negotiate or assess cost-effectiveness. Pricing policy determines who gets treated.
Median annual US launch price of new oncology drugs rose from ~$100,000 (2010) to over $200,000 (2020s), with weak correlation between price and clinical benefit (Vokinger, Lancet Oncol 2020). List versus net price (rebates, 340B) obscures costs; Medicare negotiation under the Inflation Reduction Act (2022) began with imbruvica (ibrutinib) among the first ten drugs (prices effective 2026) and caps Part D out-of-pocket at $2,000 (2025). Value frameworks: ASCO Value Framework, ESMO-MCBS, NCCN Evidence Blocks, ICER cost-effectiveness reviews, NICE thresholds (£20,000-30,000/QALY; Cancer Drugs Fund for managed access), Germany's AMNOG benefit assessment. International reference pricing, biosimilar/generic entry (imatinib price fell >90% after 2016 US generics), compulsory licensing and tiered pricing shape global access. Transparency initiatives (WHO 2019 resolution, US hospital price transparency rule) have had limited effect on net prices.
Pages like this
not linked directly; found by shared links- TermOncology workforce
Shares Global oncology and access in low- and middle-income countries and the tags gap-fill, policy.
- TechnologyTelehealth and hospital-at-home in oncology
Shares Financial toxicity and financial navigation, Global oncology and access in low- and middle-income countries and the tag gap-fill.
- TermCancer health disparities and equity
Shares Financial toxicity and financial navigation, Financial toxicity, Global oncology and access in low- and middle-income countries and the tag gap-fill.
- CollectionASCO clinical practice guidelines
Shares NICE cancer guidance and technology appraisals (UK) and the tag gap-fill.
- TechnologyGrowth factors: G-CSF and febrile neutropenia prevention
Shares Biosimilar and the tag gap-fill.
- TechnologySurvivorship care and late-effects surveillance
Shares Financial toxicity and financial navigation and the tag gap-fill.
- TechnologyEarly integrated palliative care
Shares Global oncology and access in low- and middle-income countries and the tag gap-fill.
- CancerWilms tumour (nephroblastoma)
Shares Global oncology and access in low- and middle-income countries and the tag gap-fill.